Glecaprevir & Pibrentasvir

BreastfeedingPediatric

FDA APPROVAL DATE: 08/03/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atazanavir, Atorvastatin, Carbamazepine, Cyclosporine, Darunavir, Efavirenz, Lopinavir, Lovastatin, Oral Contraceptives, Rifampin, Ritonavir, Simvastatin, St John's Wort

PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk

Contra-indicated in patients with severe hepatic impairment (Child-Pugh C).

RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV

See full prescribing information for complete boxed warning.

Our database has 11 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
ENDOCRINE/METABOLIC
HEMATOLOGIC
OTHER


Page last updated 11/06/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric